Question 1

What specific risks of herpetic infections should I be aware of while on IMLYGIC?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection clinical trial (NCT02910557). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my close contacts be affected by my treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection clinical trial (NCT02910557). Contact the study team or your healthcare provider for specific answers.

Question 3

What monitoring will be done to ensure my safety during and after treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection clinical trial (NCT02910557). Contact the study team or your healthcare provider for specific answers.

Question 4

Can you explain how this study's findings might relate to my treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection clinical trial (NCT02910557). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I do if I notice symptoms of a herpetic infection?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection clinical trial (NCT02910557). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any other studies or treatments I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection clinical trial (NCT02910557). Contact the study team or your healthcare provider for specific answers.

What this study is about